Bavi et al. reported that DR4 was also significantly up-regulated in CRC and adenomas by immunohistochemistry and was associated with a less aggressive phenotype characterized by early stage disease, whereas DR5 was associated with a microsatellite stable (MS–S/L) phenotype and with absence of KRAS mutations in a Middle-Eastern population24. This evidence concerns the gene TNFRSF10A and colorectal carcinoma.